Friess G G, Boyd J F, Geer M R, Garcia J C
Cancer. 1985 Dec 15;56(12):2762-4. doi: 10.1002/1097-0142(19851215)56:12<2762::aid-cncr2820561207>3.0.co;2-e.
Doxorubicin has been reported to cause ventricular arrhythmias and sudden death in the first 24 hours after administration. The authors placed continuous electrocardiographic recording devices on 30 patients 24 hours before, during, and 24 hours after doxorubicin administration. Nine patients experienced arrhythmias before treatment; 12 patients had posttreatment ectopy. No patient had life-threatening arrhythmias before or after treatment. Of the nine patients with pretreatment ectopy, only one experienced an increase in severity. Conversely, six patients without ectopy before treatment had arrhythmias after doxorubicin administration. The authors were unable to determine predictive factors in patients with no pretreatment ectopy who developed posttreatment premature ventricular contractions. The authors conclude that antecedent ventricular ectopy exists in the oncologic population and that this is not worsened by first-dose exposure to doxorubicin.
据报道，阿霉素在给药后的头24小时内可导致室性心律失常和猝死。作者在30例患者使用阿霉素前24小时、用药期间及用药后24小时放置了连续心电图记录装置。9例患者在治疗前出现心律失常；12例患者治疗后有异位心律。治疗前后均无患者出现危及生命的心律失常。在9例治疗前有异位心律的患者中，只有1例病情加重。相反，6例治疗前无异位心律的患者在使用阿霉素后出现了心律失常。作者无法确定治疗前无异位心律但治疗后发生室性早搏的患者的预测因素。作者得出结论，肿瘤患者中存在既往室性异位心律，且首次接触阿霉素不会使其恶化。
